NCT06631092View on ClinicalTrials.gov

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Triple Negative Breast Cancer
Interventions
BIOLOGICAL

Oral DNA Vaccine

Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine

Trial Locations (2)

Unknown

RECRUITING

University Clinic Erlangen, Erlangen

RECRUITING

National Center for Tumor Diseases Heidelberg, Heidelberg

Sponsors

Lead Sponsor

NEC Bio B.V

Collaborators (1)

NEC Bio Therapeutics
All Listed Sponsors
collaborator

NEC Bio Therapeutics

INDUSTRY

lead

NEC Bio B.V

INDUSTRY

NCT06631092 - Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter